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Background. Peramivir, an investigational intravenous neuraminidase inhibitor in Phase 3 trials for
hospitalized patients, was made available during the 2009 H1N1 inﬂuenza pandemic under the Emergency
Investigational New Drug (eIND) regulations. We describe the clinical characteristics and outcomes of all patients
for whom peramivir was requested under the eIND.
Methods. After obtaining eIND approval from the Food and Drug Administration and local institutional
review board approval, clinicians caring for hospitalized patients with inﬂuenza administered intravenous peramivir
and collected information on demographic characteristics, clinical characteristics, and outcomes.
Results. From April through October 2009, peramivir was requested for 42 patients and administered to 20
adults and 11 children. At hospitalization, all patients had rapidly progressing, radiographically conﬁrmed viral
pneumonia with respiratory failure, and all but 1 patient required mechanical ventilation. In most patients,
including 1 person with documented oseltamivir-resistant infection, the illness had progressed despite oseltamivir
treatment. Peramivir was administered for 1–14 days (median duration, 10 days). The 14-day, 28-day, and 56-day
survival rates were 76.7%, 66.7%, and 59.0%, respectively. Peramivir was generally well tolerated.
Conclusions. Intravenous peramivir was well tolerated and was associated with recovery in most patients
hospitalized with severe 2009 H1N1 inﬂuenza viral pneumonia and treated under an eIND.
On 26 April 2009, the US Secretary of Health and Hu-
man Services declared a public health emergency due to
the 2009 inﬂuenza A H1N1 virus (2009 H1N1) infection
pandemic [1]. Compared with seasonal inﬂuenza, the
number of hospitalizations, admission to intensive care
units, and invasive life support were disproportionately
high among children and young adults [2–4], whereas
underlying medical conditions, especially immunosup-
pression, obesity, and pregnancy, were identiﬁed as risk
factors for hospitalization [2, 3, 5, 6]. In the face of this
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MAJOR ARTICLEemergency and the lack of Food and Drug Administration
(FDA)–approved intravenous (IV) neuraminidase inhibitors
(NAIs) to treat seriously ill hospitalized patients, the FDA acted
to make peramivir, an investigational IV NAI, available.
Use of NAIs in previously healthy outpatients with un-
complicated seasonal inﬂuenza is associated with a reduction in
the duration of viral shedding and in the duration of clinical
signs and symptoms [7, 8]. Retrospective studies involving
hospitalized patients withinﬂuenzahavereporteda reduction in
viral replication, improved survival, and possibly shorter dura-
tion of hospitalization when NAIs are used early in the course of
illness [9, 10]. Based on these data and on early data among
hospitalized patients infected with 2009 H1N1 [3, 4], the Cen-
ters for Disease Control and Prevention and the World Health
Organization recommended early institution of antivirals for
all hospitalized persons with suspected or conﬁrmed inﬂuenza
[11, 12].
Peramivir, like the FDA-approved NAIs oseltamivir (oral)
and zanamivir (inhaled), inhibits the viral neuraminidase
enzyme and is active against inﬂuenza A and B virus, in-
cluding the novel 2009 H1N1 virus in in vitro assays and
animal models [13–16]. Over 2300 subjects, either healthy or
with inﬂuenza infection, have received peramivir in clinical
trials, where it has been generally well tolerated. Receipt of
peramivir reduced time to alleviation of symptoms, compared
with placebo [17], and demonstrated clinical efﬁcacy and
tolerability similar to that of oral oseltamivir in outpatients
[18] and in hospitalized adults with seasonal inﬂuenza
[19]. Peramivir is currently undergoing US Phase 3 trials in-
volving hospitalized patients with inﬂuenza and was recently
approved in Japan and South Korea.
To make peramivir available by Emergency Use Authoriza-
tion (EUA), the FDA initiated a series of site visits and audits,
review of data, and preparation of documentation for clinicians.
While these steps occurred (April–October 2009), the FDA re-
quested that BioCryst Pharmaceuticals provide peramivir under
FDA Emergency Investigational New Drug (eIND) regulations
(21 CFR 312.56) to treat individual severely ill hospitalized pa-
tients upon request from any licensed clinician in the United
States. The EUA was initiated on 23 October 2009 [20], effec-
tively ending the eIND.
This report is a retrospective review of all patients for whom
eIND requests for peramivir were received by BioCryst for the
treatment of conﬁrmed or suspected 2009 inﬂuenza A(H1N1)
from April through 23 October 2009.
METHODS
Under the conditions of the eIND process, clinicians re-
quested peramivir if they believed that such use was in the best
Figure 1. Cumulative requests received for peramivir from April through 23 October 2009 under the Emergency Investigational New Drug (eIND)
regulations.
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by the FDA or BioCryst nor were subjects required to have
experienced the failure of other drug regimens. The avail-
ability of this investigational IV NAI was made public through
the BioCryst web site, through the media, and by personal
communication.
Upon notiﬁcation of FDA eIND approval from the clinician,
BioCryst provided the drug, investigator brochure, drug dosing
and preparation instructions, and a sample informed consent
form. The clinician obtainedinstitutional review boardapproval
and informed consent and submitted the required documenta-
tion to the FDA within 5 days of drug initiation.
Peramivir was supplied in 200 mg/20 mL single-use vials to be
dilutedin sodium chloride injection, UnitedStatesPharmacopeia.
The adult recommended dosage was 600 mg IV once daily, with
adjustments for renal impairment. Because no pediatric patients
had received peramivir, the recommended pediatric dosage was
based upon pharmacokinetic modeling, ranging from 6 mg/kg to
12 mg/kg, not to exceed 600 mg IV per day [14]. Within 2 weeks
of the patient’s last peramivir dose, all unused drug was to be
destroyed.
Data were collected using a standardized case report form to
assess demographic characteristics, underlying conditions, ill-
ness onset and severity, laboratory results, treatment, and out-
comes. Severity of illness was assessed using a modiﬁed Acute
Physiology and Chronic Health Evaluation (APACHE) II score
calculated from data submitted with the request. In the event of
a serious adverse event or death, a MedWatch form was to be
submitted to the FDA and a copy sent to BioCryst. Data were
collected for patients for at least 56 days after peramivir treat-
ment was initiated. Follow-up status as of February 2010 was
determined by case report form data; missing data were clariﬁed
via direct email or telephone contact with the patient’s clinician.
Upon request from clinicians, blood samples were shipped to
BioCryst for therapeutic drug monitoring (TDM), as previously
described [21].
Demographic and clinical characteristics were summarized
using descriptive statistics. Univariate logistical regression was
performed to assess the potential risk factors predictive of
mortality. Odds ratios and 95% conﬁdence intervals (CIs) were
calculated for each factor. Survival at 14, 28, and 56 days was
estimated based on the method of Kaplan-Meier.
RESULTS
eIND Requests
Requests for peramivir were received for 42 patients from 18
states from April 2009 through 23 October 2009. Three re-
quests were received in May and June, and the remaining 39
requests were received from September through October,
correlating with the second wave of pandemic inﬂuenza in the
Table 1. Demographic Characteristics and Co-morbidities on
Day of eIND Request
Parameter
Peramivir-treated
patients (n 5 31)
Age group
a
0–4 1 (3)
5–9 2 (6)
10–17 8 (26)
18–49 14 (45)
50–64 5 (16)
>65 1 (3)
Sex
Male 18 (58)
Female 13 (42)
Race
Caucasian 28 (90)
Other 3 (10)
Ethnicity
Non-Hispanic 23 (74)
Hispanic 7 (23)
Unspeciﬁed 1 (3)
BMI, median value (range) 28 (12.5–50.0)
Prior medical condition
Obesity (BMI > 30) 11/31 (35)
Severe obesity (BMI > 40) 3/31 (10)
COPD/asthma 7/31 (23)
Pregnant or post-partum 3/13 (23)
Cancer 2/31 (6)
Diabetes 3/31 (10)
Solid-organ transplantation 2/31 (6)
Hematopoietic stem cell
transplantation
1/31 (3)
Corticosteroid use 5/31 (16)
Inﬂuenza severity
Pneumonia with respiratory failure 31/31 (100)
Mechanical ventilation required 30/31 (97)
Vasopressor support required 17/31 (55)
APACHE II score > 20 19/31 (61)
Acute renal failure 13/31 (42)
Dialysis required 11/31 (35)
Acute heart failure 6/31 (19)
Liver failure 4/31 (13)
APACHE II score, median value (range) 22 (5–37)
Other neuraminadase treatment
Oseltamivir 27/31 (87)
Zanamivir 1/31 (3)
None 3/31 (10)
Unknown 1/31 (3)
NOTE. Data are no. (%) or proportion (%) of patients, unless otherwise
indicated. APACHE, Acute Physiology and Chronic Health Evaluation; BMI,
body mass index, calculated as the weight in kilograms divided by the square
of height in meters; COPD, chronic obstructive pulmonary disease.
a The median age of the patients was 23.0 years (range, 3 months to 76
years).
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Age Sex Presentation
Prior
TX
Peramivir
TX Clinical course Outcome Comments
Pediatric patients
15 M Fever,
pneumonia,
CHF,
respiratory
failure,
myocarditis.
O, A HD6–16
600 mg/d
HD1: intubation,
ECMO, mechanical
ventilation. Pulmonary
improvement with
peramivir. Multiple
medical complications.
Vasopressor support
due to heart failure.
Transferred from
PICU to another
hospital on
HD110
Awaiting heart
transplant
17 M 3-d HX URI.
Pneumonia.
O HD3–8
600 mg/d
Respiratory failure,
intubation, mechanical
ventilation, worsening
to require HFO.
Vasopressor support.
Renal failure.
Pulmonary improvement
with peramivir.
Extubation HD19.
Cardiac and
hepatic dysfunction
persisted.
Discharged HD27.
Recovered Rehab required
15 F Pneumonia. O, A, RHD6–7
600 mg/d
HD3: Intubation,
mechanical ventilation,
HFO. Vasopressor
support. Initial
improvement on
peramivir.
Worsening HD7
required transfer
to hospital
with ECMO.
Peramivir discontinued.
Recovered On HD25, patient
improved
and off ventilator
support.
Eventually discharged
home.
10 M 5-d HX URI.
Pneumonia,
leucopenia,
respiratory
failure,
renal failure.
O HD8–22
2.2 mg/kg
adjusted to
5.4 mg/kg
with TDM
ARDS, intubation.
Progressive respiratory
failure. ECMO initiated
on HD7. Renal failure
required CVVH.
Immunosuppressive
drugs discontinued.
Hypotension requiring
inotropic support.
Viral shedding
continued through
HD14; absent HD37.
Extubated HD43.
Discharged HD72.
Recovered HX renal transplant.
H275Y mutation,
O resistance
11 F 5-d HX fevers,
HA, URI,
vomiting, diarrhea.
Pneumonia,
acrocyanosis.
O HD2–12
10 mg/kg
Respiratory failure,
intubation, mechanical
ventilation. Clinical
status improved.
Extubated HD6.
Radiographs HD7
showed complete
resolution.
Discharged HD12 in
stable condition.
Recovered Peramivir PK
on HD3 shown in Figure 2
and chest radiographs
on HD1 and HD9 in
Suppl. Appendix.
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Age Sex Presentation
Prior
TX
Peramivir
TX Clinical course Outcome Comments
13 M Inﬂuenza. O HD16–25
600 mg/d
Respiratory failure,
intubation, mechanical
ventilation, ECMO.
Vasopressor support.
Improvement in
respiratory and
hemodynamic parameters
after peramivir.
HD30: remained
critically ill on ECMO.
Died HD53
a HX of asthma
5 M 14-d HX URI. O HD16–26
10 mg/kg
Respiratory failure,
intubation, mechanical
ventilation HD5 and
eventually ECMO.
Clinically comatose,
heart failure.
Died HD34
a Medical support
withdrawn
per family request.
0.3 F 2-d HX inﬂuenza. O HD2–12
2.2 mg/kg
adjusted
by TDM
HD1: hypotension,
unresponsiveness
requiring intubation,
myocarditis, intracranial
hemorrhage, acute
renal failure requiring
CVVH, ECMO.
Cardiac contractility
improved dramatically
with peramivir.
ECMO continued
6 days. Renal failure
reversing by HD6.
Line-related Candida
infection and CA-MRSA
treated. Discharged HD57.
Recovered
14 F 4-d HX URI.
Pneumonia and
respiratory failure.
O HD14–20
10 mg/kg
Respiratory failure,
intubation, mechanical
ventilation. Deteriorated,
requiring HFO and
vasopressor support.
Died HD20
a HX of asthma and
chronic
renal failure
13 M HX URI. HD2–10
10 mg/kg
HD1: pneumonia,
respiratory failure,
intubation, mechanical
ventilation. Vasopressor
support. Respiratory status
improved on peramivir.
Discharged home HD14.
Recovered
8 M 4-d HX otitis
media. Respiratory
distress, cyanosis
and impending
respiratory failure.
O HD10–18
10 mg/kg
Cardiac arrest HD1
with resuscitation,
intubation. Radiographs
with severe atelectasis.
Intubated, mechanically
ventilated. Worsening
oxygenation led to
ECMO on HD3. Lung
function improved
by HD14, allowing
decannulation and HFO.
MRI HD31 revealed
diffuse cerebral ischemia
and atrophy, likely
sequelae of
cardiopulmonary arrest.
Died HD35
a HX Noonan syndrome,
congenital heart disease
and defects, congenital
pulmonary hypertension,
spinal fusion for scoliosis.
Medical support
withdrawn
per family request.
Chest radiographs HD10
and HD19 in
Supplemental Appendix.
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Median time from eIND request to drug receipt was 21 h
(range, 3–50 h); the time required for shipping drug supply
from a central repository was the major contributor (range,
,1t o4 8h )t ot h i sd e l a y .I n9c a s e s ,t h ed r u gw a sn o ta d -
ministered because death (n 5 5) or recovery (n 5 4) ensued
prior to drug administration. Peramivir was administered to
the remaining 31 patients; all subsequent results reﬂect data
collected from only those treated patients.
Clinical and Virologic Findings
Peramivir-treated patients were mostly children and young
adults (Table 1; Supplementary Appendix Tables S1-S2).
Eleven patients (35%) were ,1 8y e a r so fa g e ,a n d3o f1 3
women were pregnant (n 5 2) or immediately post-partum
(n 5 1). All patients were admitted to an intensive care unit
with fever and rapidly progressing radiologically conﬁrmed
pneumonia. Most patients (55%) were without known un-
derlying medical conditions prior to inﬂuenza onset; 11 pa-
tients (35%) were obese (deﬁned as a body mass index >30,
calculated as the weight in kilograms divided by the square of
height in meters). Six of these 11 patients had no other un-
derlying conditions. Common underlying conditions were
asthma or chronic obstructive pulmonary disease (23%) and
compromised immunity (23%). Laboratory ﬁndings are
summarized in Supplementary Appendix Tables S3–S4. Pa-
tients with eIND requests who did not receive peramivir had
similar demographic characteristics and medical conditions
(Supplementary Appendix Table S5).
Infection with inﬂuenza A virus was conﬁrmed during hos-
pitalization by real-time polymerase chain reaction or culture in
26 (84%) of the 31 treated patients; other diagnostic methods,
such as immunoﬂuorescence, were used for the other patients.
In 23 cases, 2009 H1N1 subtype was conﬁrmed; for the re-
maining cases, 2009 H1N1 subtype was epidemiologically pre-
sumed. In 1 case, inﬂuenza viral RNA was detected in
extrapulmonary samples, including plasma and stool samples
[22]. In another case, inﬂuenza A(H1N1) virus with the H275Y
neuraminidase mutation was detected by pyrosequencing
assay and conﬁrmed by culture performed at the Centers
for Disease Control and Prevention (L. Gubareva, personal
communication).
Table 2. (Continued)
Age Sex Presentation
Prior
TX
Peramivir
TX Clinical course Outcome Comments
Pregnant/post-partum patients
28 F 3-d HX symptoms.
Pneumonia.
O HD6–15 Respiratory failure,
intubation, mechanical
ventilation. Emergency
C-section delivered
healthy baby HD2.
Respiratory deterioration
requiring high FiO2,
PEEP. Clinical status
improved gradually.
Tracheostomy with
insertion of PEG tube.
Transferred to LT care HD23.
Continued improvement,
extubation.
Recovered Peramivir PK on HD8
shown in Figure 3.
22 F 7-d HX symptoms.
Pneumonia.
O HD4–8 Respiratory failure,
intubation, mechanical
ventilation, AC.
Vasopressor support.
Discharged HD12.
Recovered HX of asthma.
Subsequently
delivered healthy baby.
23 F 4-d HX ILI.
Pneumonia and
respiratory failure.
O HD2–12 Respiratory failure,
intubation, mechanical
ventilation. Oseltamivir
treatment initiated
HD1 for 3 days.
Recovered slowly;
extubated after 27 days.
Discharged HD38.
Recovered HX of asthma.
Twenty-two weeks
pregnant.
Subsequently delivered
healthy baby.
NOTE. A, amantadine; AC, assist control; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; CVVH, continuous venovenous
hemoﬁltration; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; HA, headache; HD, hospital day; HFO, high-frequency oscillation;
HX, history; ILI, inﬂuenza-like illness; LT, long term; O, oseltamivir; PEEP, positive end expiratory pressure; PEG, percutaneous endoscopic gastrostomy; PICU,
pediatric intensive care unit; R, ribavirin; TDM, therapeutic drug monitoring; TX, treatment; URI, upper respiratory infection.
a See primary cause of death in Table 3; PK, pharmacokinetic.
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tients (due to Staphylococcus aureus, Enterobacter cloacae, and an
unspeciﬁed pathogen), all of whom died.
Treatment
Patients had been symptomatic for a median of 12 days
(range, 3–30 days) and hospitalized for a median of 4 days
(range, 1–24 days) prior to the initiation of peramivir and
were treated for 1–14 days (median duration, 10 days). Most
patients (27 [87%] of 31) had progressive disease despite NAI
treatment either before or during hospitalization (Table 1;
Supplementary Appendix Tables S1-S2), and 17 continued
oseltamivir treatment after initiation of peramivir. Almost all
patients (30 of 31) required mechanical ventilation, which
often included the use of high-frequency oscillatory ventila-
tion or extracorporeal membrane oxygenation (ECMO). In
13 (42%) of 31, inﬂuenza infection was complicated by acute
renal failure, which required renal replacement therapy with
hemodialysis, hemoﬁltration, or hemodiaﬁltration in 11
(35%) of 31 patients. In the majority of cases (55%), vaso-
pressor support was also required.
Because this is the ﬁrst report of peramivir treatment in
children or pregnant/post-partum women, detailed information
on the presentation, treatment, and clinical course of each of
those patients is provided in Table 2.
Therapeutic drug monitoring was performed at the inves-
tigators’ request in 7 adults and 4 children, 7 of whom required
continuous renal replacement therapy (CRRT) (Supplementary
Appendix Table S6). In previously reported results for 2 patients
receiving CRRT [21] and in 5 other eIND patients, the clearance
of peramivir was high and correlated with the degree of cor-
rection provided. An additional patient had 2 serum samples
obtained; no additional information is available. In addition, an
11-year-old female patient (Figure 2) and a 15-year-old male
patient who were not undergoing dialysis and were treated with
10 mg/kg and 600 mg of peramivir daily, respectively, after
failure of oseltamivir treatment had exposures similar to those
observed in adults [14, 21, 23, 24]. In a 28-year-old, 4-day post-
partum woman with disease progression despite 4 days of
oseltamivir treatment who was not undergoing dialysis, peak
drug levels were approximately one-third the average levels
observedinhealthynonpregnantvolunteersaftertreatmentwith
peramivir 600 mg IV daily [14, 24] (Figure 3).
Outcome
Despite the severity of illness, survival at 14, 28, and 56 days
after initiation of peramivir treatment was 76.7%, 66.7%, and
59.0%, respectively (Figure 4). In some cases, the primary
cause of death was unresolved respiratory failure and adult
respiratory distress syndrome (ARDS), but in other cases,
death occurred because of the failure of other organ systems
or complications reﬂecting underlying medical conditions
(Table 3). Univariate analysis showed a signiﬁcantly increased
risk for mortality in men (odds ratio [OR], 6.87; 95% CI,
1.17–40.37; P 5 .03) and patients with higher APACHE II
scores (OR, 1.14; 95% CI, 1.01–1.29; P 5 .04) (Table 4). No
signiﬁcant mortality effect of increasing age or time to per-
amivir treatment was observed in our small case series.
However, the 10 pediatric patients and pregnant or post-
partum patients who recovered received peramivir starting on
hospital day 2–8, whereas the 4 patients who died received
peramivir starting on hospital day 10–16 (Table 2).
Patients who recovered were discharged from the hospital
after 8–117 days (median duration, 25 days). Peramivir treat-
ment was generally well tolerated; no reports of serious adverse
events or adverse events attributable to peramivir were received
by BioCryst.
Figure 2. Semi-logarithmic concentration of peramivir over time after the second dose of 10 mg/kg/day in patient 8, an 11-year-old girl who recovered.
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In this review of hospitalized, critically ill patients with pan-
demic inﬂuenza, antiviral therapy with intravenous peramivir
appears to have reduced mortality and to have been well
tolerated. The uncontrolled nature of this observational re-
port, however, makes assessment of efﬁcacy and safety difﬁ-
cult. The data provide insight into the clinical impact and
pharmacokinetics of peramivir in children, pregnant women,
and patients with acute renal failure. The risk factors associ-
ated with mortality in this small series were more-severe
disease and male sex, which are consistent with some previous
reports [5, 25, 26].
This eIND experience represents the ﬁrst report of peramivir
administration in children, pregnant or post-partum women,
and patients with acute renal failure, some of whom underwent
TDM. The majority of patients in this 2009 H1N1–infected,
severely ill, hospitalized population were children and young,
otherwise healthy adults, in contrast to the older population
hospitalized during typical inﬂuenza seasons [2]. Obesity was
seen in 35% of patients, and half of the obese patients were
without other risk factors for severe disease, ﬁndings that are
consistent with the wider experience with hospitalizations dur-
ing the pandemic [2]. Pregnant women have been over-
representedinthepopulationsofpatientshospitalizedwith2009
H1N1 infection, often with rapidly progressive severe disease [2,
6]. Seven (64%) of 11 treated children and all pregnant or post-
partum women survived in our case series. TDM in 2 pediatric
patients who received 10 mg/kg to a maximum of 600 mg/day,
which is a dose recommended on the basis of pharmacokinetic
modeling, revealed peramivir exposures similar to those found
in adults [14, 21, 23, 24], whereas peak drug levels in a post-
partum woman were lower but were still far above the levels
Figure 3. Semi-logarithmic concentration of peramivir over time after the third dose of 600 mg/day in patient 10, a post-partum woman who recovered.
Figure 4. Kaplan-Meier survival curve.
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needed on the pharmacokinetics of peramivir in these sub-
populations; higher dosages may be needed for patients during
pregnancy and the early post-partum period.
As in previous reports [2, 3], renal failure was a complication
of inﬂuenza infection, severe pneumonia, and ARDS in this case
series and appears to have been associated with an increased risk
of mortality. Because peramivir undergoes little metabolism in
Table 3. Primary Cause and Timing of Death for 12 Patients Who Died
Primary cause of death
Days after
hospitalization
Days after
peramivir start Age, years
Acute lung injury, ARDS, MODS, pneumonia, renal failure 5 2 41
Heart failure, bacterial pneumonia, respiratory failure, kidney failure 6 4 18
Acute lung injury, ARDS, MODS, pneumonia 6 4 27
MODS, cardiac arrest, ARDS, pneumonia, MI, dysrrhythmia, kidney and liver failure 10 1 55
Multi-organ failure, acute lung injury, ARDS, pneumonia, dysrrhythmia, renal failure, encephalitis 12 4 53
Pneumonia, respiratory failure 12 5 76
Pneumonia, multi-organ failure 16 15 54
Viral and bacterial pneumonia, respiratory failure 19 9 14
Uncontrollable hemorrhage, MODS, DIC, shock, renal failure, vascular insufﬁciency, cholecys-
titis, decreased cardiac function
33 8
a 5
Global encephalopathy due to resuscitated cardiopulmonary arrest 34 25
a 8
Sepsis and bacterial pneumonia 37 35
a 38
Pneumonia, respiratory failure 53 38 13
NOTE. Primary cause of death according to the physician requesting intravenous peramivir. ARDS, adult respiratory distress syndrome; DIC, disseminated
intravascular coagulation; MI, myocardial infarction; MODS, multi-organ dysfunction syndrome.
a Medical support withdrawn at family request.
Table 4. Risk Factors for Mortality in Peramivir-Treated Patients
Parameter Alive(n519) Dead(n512) Odds ratio(95% CI) P
Age, median years (range) 23 (0.3–51) 32 (5–76) 1.02 (0.98–1.07) .25
Children ,18 years of age 7/19 (37) 4/12 (33) 0.86 (0.19–3.92) .84
Sex, M/F (% F) 8/11 (58) 10/2 (17) 6.87 (1.17–40.37) .03
BMI, median value (range) 28.3 (12.5–44.2) 27.4 (15.9–50.0) 1.03 (0.94–1.12) .52
BMI > 30 6/19 (32) 5/12 (42) 1.55 (0.34–6.94) .57
Immunocompromised
a 4/19 (21) 3/12 (25) 1.25 (0.23–6.91) .80
Lung disease 4/19 (21) 3/12 (25) 1.25 (0.23–6.91) .80
Pregnant or post-partum 3 0 NA
Vasopressor support required 10/19 (53) 7/12 (58) 1.26 (0.29–5.42) .76
APACHE II score, median value (range) 17 (5–36) 25 (16–37) 1.14 (1.01–1.29) .04
APACHE II score >20 9/19 (47) 10/12 (83) 5.56 (0.95–32.46) .06
Use of HFO/ECMO 7/19 (37) 6/12 (50) 1.71 (0.40–7.43) .47
Use of CVVH/SLED/CVVHDF/CVVHD/CRRT 4/19 (21) 4/12 (33) 1.88 (0.37–9.57) .45
Duration illness before peramivir, median days (range) 11 (3–26) 14 (5–29) 1.06 (0.93–1.21) .40
Duration of hospitalization before peramivir, median days (range) 4 (1–24) 7 (1–15) 1.07 (0.93–1.22) .37
Use of other NAIs 17/19 (89) 10/12 (83) 0.59 (0.07–4.85) .62
Concomitant use of peramivir and oseltamivir 12/19 (63) 5/12 (42) 0.42 (0.10–1.83) .25
Duration of illness before any NAI use, median days (range) 4.5 (-6 to 18) 7.0 (4–16) 1.12 (0.96–1.32) .16
Duration of illness before oseltamivir or zanamivir use, median days (range) 4.0 (-6 to 18) 7.0 (4–14) 1.14 (0.93–1.41) .20
Duration from other NAI use to peramivir use, median days (range) 4 (1–22) 4 (1–15) 1.01 (0.86–1.19) .89
NOTE. Data are no. (%) or proportion (%) of patients, unless otherwise indicated. APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass
index, calculated as the weight in kilograms divided by the square of height in meters; CI, conﬁdence interval; CVVH, continuous venovenous hemoﬁltration;
CVVHDF, continuous venovenous hemodiaﬁltration; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; HFO, high-
frequency oscillation; SLED, slow low efﬁciency dialysis.
aImmunocompromised patients were those having had prior chronic corticosteroid use, diabetes, chronic renal failure, solid-organ transplant, and/or hematopoietic
stem cell transplantation.
Emergency IND Use of Peramivir d CID 2011:52 (15 March) d 703humans and is eliminated unchanged in the urine, drug clear-
ance correlates with creatinine clearance [27]. Our experience
with 7 eIND patients and the experience of 2 patients treated
under the EUA [23], all of whom had acute renal failure and
TDMafterdoseadjustmentofIVperamivirtodosagesashighas
600 mg IV once daily, revealed no evidence of drug-induced
toxicity and suggests a high clearance of peramivir by CRRT.
Based on these results, current guidance includes dose adjust-
ment according to the type and duration of CRRT provided
[14]. Further study is needed to provide more-speciﬁc guidance
for dose adjustment in subjects with acute renal failure, partic-
ularly those undergoing different modalities of renal re-
placement therapy, and such studies are ongoing.
Although not a statistically signiﬁcant factor, earlier initiation
of IV peramivir may have been associated with reduced mor-
tality in the eIND cases, consistent with previous reports of the
value of early intervention with NAI for both pandemic and
seasonal inﬂuenza [2, 9, 10, 25]. The relationship of survival to
early peramivir treatment was suggested in our population of
pediatric and pregnant or post-partum patients. In all patients,
mostof the delay in deliveringthedrugwas a delay in requesting
peramivir after hospitalization (range, 1–24 days), not a delay in
the acquisition of the drug after the eIND request was received.
Delivery of drug could be shortened in future emergencies by
distributing EUA stockpiles of intravenous NAIs, including
peramivir, in multiple repositories across the country or in
treating hospitals.
In this patient population with rapidly progressive viral
pneumonia and other associated complications, including pa-
tientsathighriskandatleast 1patient withtheH275Y mutation
inthe NAgene, wedocumenteda 59% survivalrate 56daysafter
treatmentwithperamivir.The principalcauseofdeathwasoften
listed as respiratory failure and ARDS, but some patients died
due to major organ failure or exacerbation of underlying con-
ditionsafterthepatient’sviralpneumoniawasresolved;antiviral
therapy,particularlyifitisappliedlate,wouldnotbeexpectedto
impact such mortality. Despite the delay in peramivir initiation
and the likely selection of the most-severely ill patients for
peramivir treatment,the survivalrate inour seriesiscomparable
to the 59%–86% survival of patients admitted to an ICU with
conﬁrmed or suspected 2009 H1N1 infection in early reports
worldwide [3, 4, 25]. Taken together with the data from the
Phase 2 study of peramivir [19], this suggests that peramivir is at
least as effective as alternative regimens. Because most of the
patients in this cohort had experienced a worsening condition
despite oral antiviraltherapy, systemic deliveryoftheantiviralin
this unique but hard-to-study population may be a beneﬁcial
alternative.
The data from this population are consistent with previous
reports of the clinical effects, safety, and tolerability of peramivir
[8,17–19, 28]. In describing the FDA Adverse Event Reporting
System reports from 237 of the .1300 patients who received
peramivir under the EUA from October 2009 through 23 June
2010, when the EUA expired, the authors concluded that it is
unlikely that peramivir adversely affected outcomes [28].
Resistance to anti-inﬂuenza agents, including oseltamivir and
zanamivir, is of increasing concern [29–31]. Clinical isolates
expressing the H275Y mutation show high-level oseltamivir
resistance (mean invitro50%inhibitory concentration [IC50] 6
standard deviation [SD], 679.5 6 44.5 nM) and intermediate
peramivir resistance (mean IC50 6 SD, 36.5 6 7.8 nM) without
achangeinzanamivirsusceptibility[32];the clinicalsigniﬁcance
of this ﬁnding, however, is not clear. In this series, we docu-
mented 1 patient with the H275Y mutation whose peramivir
dose resulted in exposures above the reported IC50 values [32,
33]. Data on the levels achieved in respiratory secretions, how-
ever,arelacking.Thepatientrecovered,buttheroleofperamivir
in that recovery is unclear, because serial viral samples were not
analyzed and other interventions, including discontinuation of
immunosuppressive medications and aggressive critical care
support, may have contributed to his survival. Apparent clinical
failure of IV peramivir therapy has been reported in an immu-
nocompromised individual with oseltamivir-resistant 2009
H1N1inﬂuenzaAillness[34].Zanamivirhasalsobeendelivered
IV to treat cases of oseltamivir-resistant 2009 H1N1 infection
[35], although it is not approved for this use, and it is the
currently recommended therapy for patients with proven re-
sistance secondary to the H275Y mutation [36].
Several patients in this series continued treatment with osel-
tamivir after IV peramivir was initiated. The combination of
oseltamivir and peramivir was not associated with an increased
risk of mortality. In vitro and in vivo animal studies and
pharmacokinetic interaction studies in humans have not shown
antagonism between oseltamivir and peramivir [13, 37, 38],
although one report suggests antagonism between NAIs in vitro
[39]. Combinations of antivirals with >2 different mechanisms
of action have shown a trend toward improved clinical efﬁcacy
and reduced emergence of resistant variants in hospitalized
subjects [40] and have been advocated to address the increasing
antiviral resistanceseen in circulatingisolates [13, 37]. However,
the current lack of available agents with different mechanisms of
action warrants consideration of alternative approaches, such as
the combination of NAIs [37].
Our report is limited by the small sample size and by both its
observational and its uncontrolled nature. The selection of pa-
tients was affected by limited publicity about the eIND process
and the lack of standard criteria for choosing those who would
beneﬁt from peramivir. Additionally, available data were lim-
ited; few patients had serial virologic or therapeutic drug
monitoring, and not all relevant clinical data were collected.
In conclusion, these data represent a unique experience of the
emergency treatment of adults and children with severe
704 d CID 2011:52 (15 March) d Hernandez et alinﬂuenza with IV peramivir. In this hospitalized population with
viral pneumonia that had progressed despite other antiviral
treatment, most patients survived after IV peramivir treatment.
Although peramivir may have contributed to recovery in a num-
ber of these patients, well-controlled studies of peramivir for
severe inﬂuenza are required to document the clinical and viro-
logic efﬁcacy of this novel agent, and these studies are ongoing.
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